IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation , a world leader in products and technologies to treat advanced cardiovascular disease, announced today the 2007 grant recipients from The Edwards Lifesciences Fund, a philanthropic, donor-advised fund the company established in 2005. As part of the Fund’s third annual grant cycle, more than 60 charitable organizations received grants between $5,000 and $100,000, bringing the yearly total to more than $2.5 million.
“We are proud that this year we are more than doubling the amount of money granted in 2006, and are also increasing the number of organizations supported by our Fund by nearly 40 percent,” said Michael A. Mussallem, Edwards’ chairman and CEO. “The Edwards Lifesciences Fund is supporting a growing number of organizations that strengthen our communities and help us in the fight against cardiovascular disease, further extending Edwards’ reach and impact around the world.”
Gifts from The Edwards Lifesciences Fund are categorized as either strategic or community grants. Strategic grants support programs or projects that expand awareness of cardiovascular disease, its prevention and treatment or enhance support and access to care for under-served cardiovascular patients. Community grants support programs or projects that provide opportunities for Edwards’ employee involvement, help strengthen the community and improve the quality of life.
During 2007, The Edwards Lifesciences Fund has awarded more than $2 million in strategic grants, including:
The Edwards Lifesciences Fund also awarded more than $300,000 in community grants in 2007, including:
Earlier this year, the company announced a $5 million multi-year grant to the University of California, Irvine to establish The Edwards Lifesciences Center for Advanced Cardiovascular Technology.
The complete list of organizations that received grants from The Edwards Lifesciences Fund is available at http://www.edwards.com/edwardsfund.
About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company’s global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.
Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and registered in the United States Patent and Trademark Office.
CONTACT: media, Amanda C. Fowler, +1-949-250-5070, or investors, David K.
Erickson, +1-949-250-6826, both of Edwards Lifesciences Corporation
Web site: http://www.edwards.com//
